Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

LIGAND PHARMACEUTICALS INCORPORATED

(LGND)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company. The Company is focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company's technology includes Captisol Technology, OmniAb Technologies (OMT), Icagen Ion Channel Technology Platform, Pelican Expression Technology platform and Liver Targeting Prodrug (LTP) Technology to assist companies in their work toward securing prescription drug and biologic approvals. It has partnerships and license agreements with over 130 pharmaceutical and biotechnology companies and over 300 programs that are in various stages of commercialization, development or research and are fully funded by its collaboration partners and licensees. Its partners and licensees have programs in clinical development targeting seizure, coma, cancer, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others.

Number of employees : 155 people.
Sales per Business
20192020Delta
Captisol31.4926.2%109.9659% +249.2%
Contract41.8234.8%42.6622.9% +2.03%
Royalties46.9839.1%33.8018.1% -28.06%
USD in Million
Sales per region
20192020Delta
United States120.28100%186.42100% +54.98%
USD in Million
Managers
Name Title Age Since
John L. Higgins Chief Executive Officer & Director 50 2015
Matthew William Foehr President & Chief Operating Officer 47 2015
Matthew Edward Korenberg Chief Financial Officer & Executive VP-Finance 45 2018
Eric Vajda, Dr. Vice President-Preclinical Research & Development - 2002
John W. Kozarich, Dr. Chairman 70 2003
Jason M. Aryeh Independent Director 52 2006
Todd C. Davis Independent Director 59 2011
Stephen L. Sabba, Dr. Independent Director 60 2013
Sunil Patel Independent Director 48 2011
John L. LaMattina, Dr. Independent Director 70 2011
Members of the board
Name Title Age Since
John W. Kozarich, Dr. Chairman 70 2003
Jason M. Aryeh Independent Director 52 2006
John L. Higgins Chief Executive Officer & Director 50 2015
Todd C. Davis Independent Director 59 2011
Stephen L. Sabba, Dr. Independent Director 60 2013
Sunil Patel Independent Director 48 2011
John L. LaMattina, Dr. Independent Director 70 2011
Nancy Ryan Gray, Dr. Independent Director 60 2017
Sarah Boyce Independent Director 48 2019
Jennifer Cochran, Dr. Independent Director 48 2021
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 16,676,532 15,871,387 95.2% 0 0.0% 95.2%
Shareholders
NameEquities%
The Vanguard Group, Inc. 1,722,291 10.3%
Janus Capital Management LLC 1,444,221 8.66%
Cardinal Capital Management LLC 1,088,265 6.53%
SSgA Funds Management, Inc. 859,448 5.15%
Scopia Capital Management LP 728,563 4.37%
Glenview Capital Management LLC 726,860 4.36%
Third Point LLC 705,016 4.23%
St. Denis J. Villere & Co. LLC 594,380 3.56%
Macquarie Investment Management Business Trust 593,449 3.56%
BlackRock Fund Advisors 491,010 2.94%
Holdings
NameEquities%Valuation
VIKING THERAPEUTICS, INC. (VKTX) 5,819,383 7.44% 36,545,725 USD
SEELOS THERAPEUTICS, INC. (SEEL) 1,921,581 1.88% 4,631,010 USD
Company contact information
Ligand Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
Suite 110
San Diego, CA 92121

Phone : +1.858.550.7500
Web : http://www.ligand.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Ligand Pharmaceuticals Incorporated